{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    5,
    6,
    10,
    11,
    16,
    26,
    91
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "06",
        "name": "Amendment 06",
        "scope": {
          "id": "1cc8cf5a-e9f4-494b-b661-e752bd49b2f9",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "5064c445-1404-4f91-aca7-70d9d69e4b81",
          "code": {
            "id": "4355b350-0622-4d5a-ab84-213faaa8fd68",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "e370f093-5484-474b-a8d4-c4f5c7151064",
            "type": {
              "id": "a2138994-527c-4f3d-b75b-e71a87d1c3e4",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary reasons for this amendment to Protocol BIVV009-03 (Cardinal) are to extend Part B duration from 1 to 2 years after Last Patient Out from Part A, to provide home infusion facilities to the patients (for US, the Netherlands, Norway, France, Italy, Austria, Germany, and Spain specific amendments), to add new exploratory objective of immunogenicity, to introduce additional time points when samples for ADAs against BIVV009 are collected, to specify that left over PD samples will be used to assess immunogenicity in patients who consented to future use of samples, to introduce additional time points for SLE panel in Part B, and to introduce a correction in Section 10.1 Appendix A.",
        "effectiveDate": "2019-12-19",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "5",
        "newVersion": "06"
      },
      {
        "id": "amend_2",
        "number": "5",
        "name": "Amendment 5",
        "scope": {
          "id": "a94a0690-ed23-4859-af2b-eedc0c4c8b10",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "31b4183f-cf5b-41d9-9e03-6270746fca96",
          "code": {
            "id": "f2a141bb-96e3-4f25-bd96-f6a91b3b0e8d",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "42426134-81d8-481b-a415-f3edf3e63f8c",
            "type": {
              "id": "d3cabf89-6bd7-4dd6-ae9d-23eaa6cf137e",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The following corrections or changes were made to the protocol for clarity, consistency, and accuracy: The page headers were updated with Version 5 of the protocol. The abbreviation list was updated. The tables of contents were updated. The Investigator’s and Sponsor’s agreement pages were updated with Version 5 and the date of approval. Minor grammatical and formatting changes were made throughout the protocol. Clarification as to how data corrections would be shown. Changed PK and PD postdose sample collection time from 2 hours to 1 hour postdose.",
        "effectiveDate": "2018-07-17",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "4",
        "newVersion": "5"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "Netherlands",
        "instanceType": "Country",
        "code": "NL"
      },
      {
        "id": "country_3",
        "name": "Norway",
        "instanceType": "Country",
        "code": "NO"
      },
      {
        "id": "country_4",
        "name": "France",
        "instanceType": "Country",
        "code": "FR"
      },
      {
        "id": "country_5",
        "name": "Italy",
        "instanceType": "Country",
        "code": "IT"
      },
      {
        "id": "country_6",
        "name": "Austria",
        "instanceType": "Country",
        "code": "AT"
      },
      {
        "id": "country_7",
        "name": "Germany",
        "instanceType": "Country",
        "code": "DE"
      },
      {
        "id": "country_8",
        "name": "Spain",
        "instanceType": "Country",
        "code": "ES"
      },
      {
        "id": "country_9",
        "name": "Japan",
        "instanceType": "Country",
        "code": "JP"
      },
      {
        "id": "country_10",
        "name": "Belgium",
        "instanceType": "Country",
        "code": "BE"
      },
      {
        "id": "country_11",
        "name": "United Kingdom",
        "instanceType": "Country",
        "code": "GB"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 11,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3",
        "country_4",
        "country_5",
        "country_6",
        "country_7",
        "country_8",
        "country_9",
        "country_10",
        "country_11"
      ],
      "regions": [
        "North America",
        "Europe",
        "Asia"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "06",
        "effectiveDate": "2019-12-19",
        "summary": "The primary reasons for this amendment to Protocol BIVV009-03 (Cardinal) are to extend Part B duration from 1 to 2 years after Last Patient Out from Part A, to provide home infusion facilities to the patients (for US, the Netherlands, Norway, France, Italy, Austria, Germany, and Spain specific amendments), to add new exploratory objective of immunogenicity, to introduce additional time points when samples for ADAs against BIVV009 are collected, to specify that left over PD samples will be used to assess immunogenicity in patients who consented to future use of samples, to introduce additional time points for SLE panel in Part B, and to introduce a correction in Section 10.1 Appendix A.",
        "previousVersion": "5",
        "newVersion": "06",
        "reasons": [
          "Operational",
          "Scientific",
          "Administrative"
        ]
      },
      {
        "number": "5",
        "effectiveDate": "2018-07-17",
        "summary": "The following corrections or changes were made to the protocol for clarity, consistency, and accuracy: The page headers were updated with Version 5 of the protocol. The abbreviation list was updated. The tables of contents were updated. The Investigator’s and Sponsor’s agreement pages were updated with Version 5 and the date of approval. Minor grammatical and formatting changes were made throughout the protocol. Clarification as to how data corrections would be shown. Changed PK and PD postdose sample collection time from 2 hours to 1 hour postdose.",
        "previousVersion": "4",
        "newVersion": "5",
        "reasons": [
          "Administrative",
          "Operational"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "Netherlands",
          "code": "NL"
        },
        {
          "name": "Norway",
          "code": "NO"
        },
        {
          "name": "France",
          "code": "FR"
        },
        {
          "name": "Italy",
          "code": "IT"
        },
        {
          "name": "Austria",
          "code": "AT"
        },
        {
          "name": "Germany",
          "code": "DE"
        },
        {
          "name": "Spain",
          "code": "ES"
        },
        {
          "name": "Japan",
          "code": "JP"
        },
        {
          "name": "Belgium",
          "code": "BE"
        },
        {
          "name": "United Kingdom",
          "code": "GB"
        }
      ],
      "regions": [
        "North America",
        "Europe",
        "Asia"
      ],
      "plannedSites": 55
    },
    "sites": []
  }
}